PUMA BIOTECHNOLOGY INC (PBYI) Stock Price, Quote, News and Overview
NASDAQ:PBYI - Nasdaq - US74587V1070 - Common Stock - Currency: USD
PBYI Quote, Performance and Key Statistics
3.72
+0.07 (+1.92%)
The current stock price of PBYI is 3.72 USD. In the past month the price increased by 21.17%. In the past year, price increased by 5.53%.
PBYI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.48 | 335.32B | ||
| AMGN | AMGEN INC | 13.99 | 156.11B | ||
| GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
| ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.66B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.42 | 19.51B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Related stock screener links
About PBYI
Company Profile
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Company Info
PUMA BIOTECHNOLOGY INC
10880 Wilshire Blvd., Suite 2150
Los Angeles CALIFORNIA 90024 US
CEO: Alan H. Auerbach
Employees: 172
Phone: 14242486500
PUMA BIOTECHNOLOGY INC / PBYI FAQ
What is the stock price of PUMA BIOTECHNOLOGY INC today?
The current stock price of PBYI is 3.72 USD. The price increased by 1.92% in the last trading session.
What is the ticker symbol for PUMA BIOTECHNOLOGY INC stock?
The exchange symbol of PUMA BIOTECHNOLOGY INC is PBYI and it is listed on the Nasdaq exchange.
On which exchange is PBYI stock listed?
PBYI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PUMA BIOTECHNOLOGY INC stock?
8 analysts have analysed PBYI and the average price target is 5.61 USD. This implies a price increase of 50.81% is expected in the next year compared to the current price of 3.72. Check the PUMA BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PUMA BIOTECHNOLOGY INC worth?
PUMA BIOTECHNOLOGY INC (PBYI) has a market capitalization of 184.66M USD. This makes PBYI a Micro Cap stock.
How many employees does PUMA BIOTECHNOLOGY INC have?
PUMA BIOTECHNOLOGY INC (PBYI) currently has 172 employees.
What are the support and resistance levels for PUMA BIOTECHNOLOGY INC (PBYI) stock?
PUMA BIOTECHNOLOGY INC (PBYI) has a support level at 3.23 and a resistance level at 3.73. Check the full technical report for a detailed analysis of PBYI support and resistance levels.
Is PUMA BIOTECHNOLOGY INC (PBYI) expected to grow?
The Revenue of PUMA BIOTECHNOLOGY INC (PBYI) is expected to decline by -2.74% in the next year. Check the estimates tab for more information on the PBYI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PUMA BIOTECHNOLOGY INC (PBYI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PBYI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PBYI, evaluating the profitability, health, valuation and growth aspects
- PUMA BIOTECHNOLOGY INC (PBYI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PUMA BIOTECHNOLOGY INC (PBYI) Sales and EPS estimates to see what analysts future expectations are.
- PUMA BIOTECHNOLOGY INC (PBYI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PUMA BIOTECHNOLOGY INC (PBYI) Insider and Institutional Ownership to learn about the owners and their transactions.
- PUMA BIOTECHNOLOGY INC (PBYI) Stock Chart to make your own analysis
- PUMA BIOTECHNOLOGY INC (PBYI) Latest news and press-releases to stay up to date.
Does PUMA BIOTECHNOLOGY INC (PBYI) stock pay dividends?
PBYI does not pay a dividend.
When does PUMA BIOTECHNOLOGY INC (PBYI) report earnings?
PUMA BIOTECHNOLOGY INC (PBYI) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of PUMA BIOTECHNOLOGY INC (PBYI)?
The PE ratio for PUMA BIOTECHNOLOGY INC (PBYI) is 4.83. This is based on the reported non-GAAP earnings per share of 0.77 and the current share price of 3.72 USD. Check the full fundamental report for a full analysis of the valuation metrics for PBYI.
What is the Short Interest ratio of PUMA BIOTECHNOLOGY INC (PBYI) stock?
The outstanding short interest for PUMA BIOTECHNOLOGY INC (PBYI) is 6.84% of its float. Check the ownership tab for more information on the PBYI short interest.
PBYI Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PBYI. When comparing the yearly performance of all stocks, PBYI turns out to be only a medium performer in the overall market: it outperformed 62.82% of all stocks.
PBYI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PBYI. PBYI scores excellent on profitability, but there are some minor concerns on its financial health.
PBYI Financial Highlights
Over the last trailing twelve months PBYI reported a non-GAAP Earnings per Share(EPS) of 0.77. The EPS increased by 133.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.36% | ||
| ROA | 19.4% | ||
| ROE | 39.2% | ||
| Debt/Equity | 0.11 |
PBYI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to PBYI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -32.84% and a revenue growth -2.74% for PBYI